| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chi-Un Pae, Andy Forbes, Ashwin A Patka. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS drugs. vol 25. issue 2. 2011-07-29. PMID:21254788. |
aripiprazole is a partial agonist at dopamine d(2) and d(3) and serotonin 5-ht(1a) receptors, and is an antagonist at 5-ht(2a) receptors. |
2011-07-29 |
2023-08-12 |
Not clear |
| Beryl Koener, Stéphanie Goursaud, Morgane Van De Stadt, André-Guilhem Calas, Anne P Jeanjean, Jean-Marie Maloteaux, Emmanuel Herman. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn-Schmiedeberg's archives of pharmacology. vol 383. issue 1. 2011-07-15. PMID:21061116. |
pharmacological blockade of dopamine d2 receptors by aripiprazole is not associated with striatal sensitization. |
2011-07-15 |
2023-08-12 |
rat |
| Beryl Koener, Stéphanie Goursaud, Morgane Van De Stadt, André-Guilhem Calas, Anne P Jeanjean, Jean-Marie Maloteaux, Emmanuel Herman. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn-Schmiedeberg's archives of pharmacology. vol 383. issue 1. 2011-07-15. PMID:21061116. |
as it is established that responses induced by dopamine d₂ receptor agonists are increased in models of dopaminergic sensitization, this paradigm was used in order to facilitate the detection of the partial agonist properties of aripiprazole. |
2011-07-15 |
2023-08-12 |
rat |
| Beryl Koener, Stéphanie Goursaud, Morgane Van De Stadt, André-Guilhem Calas, Anne P Jeanjean, Jean-Marie Maloteaux, Emmanuel Herman. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn-Schmiedeberg's archives of pharmacology. vol 383. issue 1. 2011-07-15. PMID:21061116. |
hence,aripiprazole behaved as an antagonist, efficiently inhibiting the functional response to dopamine. |
2011-07-15 |
2023-08-12 |
rat |
| Beryl Koener, Stéphanie Goursaud, Morgane Van De Stadt, André-Guilhem Calas, Anne P Jeanjean, Jean-Marie Maloteaux, Emmanuel Herman. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn-Schmiedeberg's archives of pharmacology. vol 383. issue 1. 2011-07-15. PMID:21061116. |
however, at variance with haloperidol, repeated administrations of aripiprazole(3 weeks) at the doses of 10 and 30 mg/kg did not induce any up-regulation or hyperfunctionality of the dopamine d₂ receptors in the striatum. |
2011-07-15 |
2023-08-12 |
rat |
| Beryl Koener, Stéphanie Goursaud, Morgane Van De Stadt, André-Guilhem Calas, Anne P Jeanjean, Jean-Marie Maloteaux, Emmanuel Herman. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn-Schmiedeberg's archives of pharmacology. vol 383. issue 1. 2011-07-15. PMID:21061116. |
these data highlight the putative involvement of other pharmacological targets for aripiprazole that would support in the prevention of secondary effects commonly associated with the blockade of striatal dopamine d₂ receptors. |
2011-07-15 |
2023-08-12 |
rat |
| Armida Mucci, Giuseppe Piegari, Silvana Galderis. Cognitive-enhancing effects of aripiprazole: a case report. Clinical practice and epidemiology in mental health : CP & EMH. vol 4. 2011-07-14. PMID:18959801. |
the present case report suggests cognitive enhancing effects of aripiprazole, a dopamine partial agonist, shown to increase dopamine release in prefrontal cortex in animal studies.the patient was in his first-episode of schizophrenia, and had no previous exposure to first-generation antipsychotics. |
2011-07-14 |
2023-08-12 |
Not clear |
| Hanik K Yoo, Joong-Sun Lee, Kyoung-Won Paik, Soon-Ho Choi, Sujung J Yoon, Jieun E Kim, Jin Pyo Hon. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. European child & adolescent psychiatry. vol 20. issue 3. 2011-07-08. PMID:21188439. |
due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with tic disorders. |
2011-07-08 |
2023-08-12 |
Not clear |
| Luiz Dratcu, Gavin McKay, Vinod Singaravelu, Venkat Krishnamurth. Aripiprazole treatment of Asperger's syndrome in the acute psychiatric setting: case report. Neuropsychiatric disease and treatment. vol 3. issue 1. 2011-05-17. PMID:19300548. |
his impairing clinical features of as improved markedly following treatment using aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at dopamine d(2) receptors. |
2011-05-17 |
2023-08-12 |
Not clear |
| Luiz Dratcu, Patricia Olowu, Muzafar Hawramy, Charitomeni Konstantinido. Aripiprazole in the acute treatment of male patients with schizophrenia: effectiveness, acceptability, and risks in the inner-city hospital setting. Neuropsychiatric disease and treatment. vol 2. issue 2. 2011-05-17. PMID:19412463. |
aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at the dopamine d(2) receptors, has been reported to be effective in the treatment of chronic schizophrenia. |
2011-05-17 |
2023-08-12 |
Not clear |
| Luiz Dratcu, Patricia Olowu, Muzafar Hawramy, Charitomeni Konstantinido. Aripiprazole in the acute treatment of male patients with schizophrenia: effectiveness, acceptability, and risks in the inner-city hospital setting. Neuropsychiatric disease and treatment. vol 2. issue 2. 2011-05-17. PMID:19412463. |
aripiprazole also remarkably attenuated dyskinetic movements in 1 patient with severe tardive dyskinesia, thereby suggesting that it may be useful in the treatment of other disorders that are also associated with dopamine dysfunction. |
2011-05-17 |
2023-08-12 |
Not clear |
| Athan Spiros, Robert Carr, Hugo Geert. Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatric disease and treatment. vol 6. 2011-04-28. PMID:20856922. |
using this model, we simulated the postsynaptic dopamine d(2) receptor activation levels of bifeprunox and aripiprazole, two relatively similar dopamine d(2) receptor agonists. |
2011-04-28 |
2023-08-12 |
human |
| Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, Andrea Ciarmiello, Ferdinando Squitieri, Vincenzo Silan. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatric disease and treatment. vol 5. 2011-04-26. PMID:19557093. |
the aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed huntington's disease (hd). |
2011-04-26 |
2023-08-12 |
Not clear |
| b' Pia B\\xc3\\xa4ckstr\\xc3\\xb6m, Tiina J Etel\\xc3\\xa4lahti, Petri Hyyti\\xc3\\xa. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Addiction biology. vol 16. issue 1. 2011-04-25. PMID:21158016.' |
aripiprazole is an atypical antipsychotic that acts as a partial d2 dopamine and a serotonin 5-ht₁(a) agonist and a serotonin 5-ht₂(a) antagonist. |
2011-04-25 |
2023-08-12 |
rat |
| b' Pia B\\xc3\\xa4ckstr\\xc3\\xb6m, Tiina J Etel\\xc3\\xa4lahti, Petri Hyyti\\xc3\\xa. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Addiction biology. vol 16. issue 1. 2011-04-25. PMID:21158016.' |
the increase in amphetamine self-administration with the intermediate aripiprazole dose, as well as the decrease in amphetamine-induced locomotor activity, suggests that aripiprazole acted as a dopamine antagonist. |
2011-04-25 |
2023-08-12 |
rat |
| Vuk Koprivica, Karen Regardie, Christina Wolff, Raymond Fernalld, Janelle Johnson Murphy, Junichi Kambayashi, Tetsuro Kikuchi, Shaun Jorda. Aripiprazole protects cortical neurons from glutamate toxicity. European journal of pharmacology. vol 651. issue 1-3. 2011-04-11. PMID:21093427. |
aripiprazole, the first partial dopamine d(2) receptor agonist approved for the treatment of schizophrenia, is suggested to be neuroprotective based on non-clinical studies using transformed cell lines and in vivo stress and lesion paradigms. |
2011-04-11 |
2023-08-12 |
rat |
| Vuk Koprivica, Karen Regardie, Christina Wolff, Raymond Fernalld, Janelle Johnson Murphy, Junichi Kambayashi, Tetsuro Kikuchi, Shaun Jorda. Aripiprazole protects cortical neurons from glutamate toxicity. European journal of pharmacology. vol 651. issue 1-3. 2011-04-11. PMID:21093427. |
this neuroprotective effect of aripiprazole was not mediated by the activation of serotonin 5-ht(1a) or dopamine d(2) receptors, akt or glycogen-synthase kinase-3β signaling (gsk-3β), or through the inhibition of poly-adp ribose polymerase (parp). |
2011-04-11 |
2023-08-12 |
rat |
| Gilles Gavaudan, David Magalon, Julien Cohen, Christophe Lançon, Georges Léonetti, Anne-Laure Pélissier-Alico. Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. Journal of forensic sciences. vol 55. issue 6. 2011-03-29. PMID:20579229. |
we present two patients with schizophrenia, previously treated with antipsychotic drugs without any suggestion of pg, who a short time after starting aripiprazole, a dopamine partial agonist, developed pg and criminal behavior, which totally resolved when aripiprazole was discontinued. |
2011-03-29 |
2023-08-12 |
Not clear |
| Gilles Gavaudan, David Magalon, Julien Cohen, Christophe Lançon, Georges Léonetti, Anne-Laure Pélissier-Alico. Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. Journal of forensic sciences. vol 55. issue 6. 2011-03-29. PMID:20579229. |
based on recent advances in research on pg and adverse drug reactions to dopamine agonists in parkinson's disease, we postulate a link between aripiprazole and pg in both our patients with schizophrenia and raise the question of criminal responsibility. |
2011-03-29 |
2023-08-12 |
Not clear |
| Min-Chih Cheng, Shih-Hsin Hsu, Chia-Hsiang Che. Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice. Behavioural brain research. vol 216. issue 2. 2011-03-22. PMID:20833207. |
aripiprazole is a dopamine d2/d3 receptor partial agonist that is currently used as an antipsychotic drug in clinical settings. |
2011-03-22 |
2023-08-12 |
mouse |